Prognosis
OxyContin Billionaires Chase Global Profits to Offset U.S. Woes
- Worldwide network of drug companies shores up Sackler fortune
- Mundipharma group expanding into biosimilars, new technologies
Photographer: George Frey/Bloomberg
This article is for subscribers only.
A New York state lawsuit is renewing longstanding questions about where some members of the billionaire Sackler family have invested the wealth they amassed from Purdue Pharma LP, the drugmaker accused of helping ignite the U.S. opioid epidemic.
One place where some of the Sacklers’ about $13 billion fortune appears to have flowed is to Mundipharma, a worldwide network of independent associated companies that Sackler family members control through trusts and other investment vehicles.